Insmed Slides 4.3% as Recent Insider Sales and Post-Earnings Profit-Taking Weigh on Shares
Insmed's stock dropped 4.3% due to a combination of post-earnings profit-taking and significant insider stock sales. The company had previously seen a rally after reporting strong Q2 2026 results and increased guidance for its key products. Recent regulatory filings showed several executives, including the COO and CMO, sold substantial amounts of shares after exercising options.
Insmed (NASDAQ: INSM) director sells 5,000 shares via Padonia LLC
Insmed (NASDAQ: INSM) director Melvin Sharoky, MD, indirectly sold 5,000 shares of common stock through Padonia, LLC on August 17, 2026, at a weighted average price of $127.53 per share. Following this transaction, Padonia, LLC holds zero shares, while Dr. Sharoky retains 246,081 shares directly and additional shares indirectly through his spouse and custodial accounts. The sale was not marked as being under a Rule 10b5-1 trading plan.
How Insmed’s Sharply Narrowed Q2 2026 Net Loss At Insmed (INSM) Has Changed Its Investment Story
Insmed (INSM) reported a significantly narrowed net loss in Q2 2026, dropping to US$13.24 million from US$321.69 million a year prior, indicating improved cost control. This reduction in losses, coupled with a narrowed net loss for the first half of 2026, could influence the investment narrative, particularly concerning the upcoming launches of brensocatib and the company's ability to meet its revenue guidance of over US$1.0 billion for BRINSUPRI and US$450-470 million for ARIKAYCE in 2026. While suggesting better expense management, the core investment focus remains on the success of these product launches and potential payer pushback.
Insmed (INSM) Earnings Narrow Losses As Fair Value Comes Back Into Focus
Insmed (INSM) has shown narrowed net losses in its second quarter 2026 results, boosting its share price by 3.7% in one day and 18.46% over 30 days, although it remains down 27.55% year-to-date. The company is considered significantly undervalued by many, with a fair value estimate around $197.14, driven by its pipeline including the anticipated U.S. launch of brensocatib in Q3 2025. While positive catalysts like clinical milestones are on the horizon, potential delays and payer pushback represent key risks to its future revenue growth.
Insmed (NASDAQ: INSM) holder Padonia targets $638K share sale
Padonia LLC, associated with Melvin Sharoky, has filed a Form 144 notice indicating a proposed sale of up to 5,000 shares of Insmed Inc. common stock, with an aggregate market value of approximately $637,636.84. This filing ensures transparency regarding the sale of shares on NASDAQ. The filing also references a prior purchase of 10,000 shares in May 2023.
Insmed CMO Martina Flammer sells $3.49m in company stock
Martina Flammer, CMO of INSMED Inc., sold approximately $3.49 million worth of company stock through a Rule 10b5-1 trading plan on August 6, 2026, while concurrently acquiring shares valued at $576,125 through stock option exercises. Following these transactions, Flammer directly owns 60,486 shares and holds derivative securities for additional shares. The company recently reported significant revenue increases for its drugs BRINSUPRI and ARIKAYCE, leading to raised full-year guidance and positive analyst outlooks.
13,000 Shares in Insmed, Inc. $INSM Purchased by S&CO Inc.
S&CO Inc. recently acquired 13,000 shares of Insmed, Inc. (NASDAQ:INSM) valued at approximately $1.39 million, reflecting growing institutional interest in the biopharmaceutical company. Despite significant insider selling totaling $37.8 million over the past 90 days, analysts maintain a "Buy" rating with a consensus price target of $205.52. Insmed also reported strong financial results, surpassing EPS and revenue expectations with $425.5 million in revenue, marking a 296.1% year-over-year increase.
Insmed, Inc. $INSM Shares Bought by Empowered Funds LLC
Empowered Funds LLC increased its stake in Insmed, Inc. (NASDAQ:INSM) by 32.6% in the first quarter, owning 51,986 shares worth $8.5 million. Several other institutional investors also increased their holdings in Insmed during the same period, while company insiders made significant stock sales. Analyst ratings for Insmed are predominantly "Buy," with an average price target of $205.52.
Darwin Global updates Insmed Inc (INSM) ownership, reporting 3.0% beneficial stake
Darwin Global Management, Ltd., along with its Chief Investment Officer Dr. Abhishek Trehan and Darwin Global Master Fund Ltd., has reported a beneficial ownership of 3.0% in Insmed Inc. common stock, totaling 6,431,163 shares. This stake is based on 216,752,451 shares outstanding as of May 1, 2026, and the reporting persons share voting and dispositive power over these shares, indicating an investment purpose rather than control. The filing specifies that ownership is 5 percent or less of a class, consistent with a Schedule 13G filing.
Insmed(INSM.US) Officer Sells US$31.96 Million in Common Stock
An officer at Insmed (INSM.US) recently sold a significant amount of common stock, totaling US$31.96 million. This transaction highlights an insider trading activity, which can sometimes be viewed by investors as a signal regarding the company's future prospects or valuation.
Insmed (INSM) Is Up 34.2% After Sharp Year-Over-Year Net Loss Reduction - Has The Bull Case Changed?
Insmed (INSM) saw its stock rise 34.2% following a significant reduction in its net loss for Q2 2026, narrowing to US$13.24 million from US$321.69 million a year prior. This improvement in financial performance, along with reiterated revenue guidance for its key drugs BRINSUPRI and ARIKAYCE, could positively impact the company's investment narrative. However, near-term execution risks related to drug approvals, launches, and payer access remain critical considerations for investors.
Insmed (NASDAQ:INSM) COO Sells 239,850 Shares
Insmed (NASDAQ:INSM) COO Roger Adsett sold 239,850 shares of the company's stock for approximately $32.0 million, reducing his direct holdings by over 70%. Despite the sale and a slight dip in stock price, Insmed reported better-than-expected quarterly revenue and adjusted loss per share. Analyst sentiment remains positive with an overall "Buy" rating and an average price target of $205.52.
INSMED Inc (INSM) COO exercises 239,850 options and sells matching shares
INSMED Inc.'s Chief Operating Officer, Roger Adsett, exercised 239,850 stock options at various prices and simultaneously sold an equivalent number of common shares at a weighted average price of $133.27 per share, generating an approximate pre-tax spread of $27.06 million. The transactions were direct holdings and not executed under a Rule 10b5-1 trading plan. Adsett's holdings after the transaction include 98,744 shares of common stock, with 141 shares acquired through the company's 2018 Employee Stock Purchase Plan.
Insmed Chief Operating Officer Sold Shares Worth Over $31M
Insmed Chief Operating Officer Roger Adsett sold 98,744 shares of common stock at a weighted average price of $133.27 per share, totaling over $31 million. Following this transaction, Adsett directly owns 98,744 shares. This information is based on an SEC Form 4 filing.
HC Wainwright Brokers Increase Earnings Estimates for Insmed
HC Wainwright has revised its Q3 2026 EPS estimate for Insmed, raising it to a loss of $0.31 from a projected loss of $0.82, while maintaining a "Buy" rating. The firm also anticipates Insmed will return to profitability by 2027, with an EPS of $10.92 by 2030. This upgrade follows Insmed's recent strong quarterly performance, where the company surpassed EPS and revenue expectations, demonstrating significant year-over-year revenue growth.
Insmed (INSM) Is Up 34.2% After Sharp Year-Over-Year Net Loss Reduction - Has The Bull Case Changed?
Insmed (INSM) recently announced significantly reduced net losses for Q2 2026 and the first half of 2026, boosting its stock by 34.2%. This improvement in financial performance, alongside reiterated revenue guidance for its key drugs BRINSUPRI and ARIKAYCE, suggests a more sustainable path for the company. However, the article notes that execution risks related to drug approvals, launches, and payer access remain, tempering the bull case despite the positive earnings report.
H.C. Wainwright reiterates Buy on Insmed stock, $220 target
H.C. Wainwright has reiterated a Buy rating on Insmed (NASDAQ:INSM) stock with a $220 price target, driven by the strong performance of its drug Brinsupri. Brinsupri's revenue growth exceeded expectations, with the company raising its 2026 revenue guidance for the drug to $1.25 billion to $1.4 billion. Insmed has also increased its combined peak sales estimate for its three lead assets to over $14 billion, signifying its transition to a broader respiratory franchise.
INSM (INSM) insider notice covers 239,850 shares and prior sales data
An SEC Form 144 filing by INSMED Inc. indicates a potential sale of 239,850 common shares, with an indicated trading date of August 10, 2026, on NASDAQ. The filing also discloses prior sales by Roger Adsett, including 2,370 shares on June 3, 2026, and 5,837 shares on May 13, 2026. Key figures related to the company's common stock, such as 31,963,198 and 218,381,503, are also reported.
Insmed (NASDAQ:INSM) Price Target Cut to $175.00 by Analysts at JPMorgan Chase & Co.
JPMorgan Chase & Co. has lowered its price target for Insmed (NASDAQ:INSM) to $175.00 from $179.00, while maintaining an "overweight" rating. This adjustment comes despite Insmed exceeding quarterly earnings expectations, reporting a loss of $0.06 per share against a forecasted $0.67 loss and a significant revenue increase of 296.1% year-over-year to $425.49 million. The biopharmaceutical company still holds a consensus "Buy" rating and an average price target of $205.52 from other analysts.
$1000 Invested In Insmed 5 Years Ago Would Be Worth This Much Today
Insmed (NASDAQ: INSM) has significantly outperformed the market over the last five years, with an annualized return of 41.43%. An initial investment of $1000 made five years ago would now be worth $5,573.37. This demonstrates the powerful effect of compounded returns on investment growth.
H.C. Wainwright reiterates Buy on Insmed stock, $220 target
H.C. Wainwright has reiterated a Buy rating and a $220 price target for Insmed (NASDAQ:INSM) stock, citing the strong early performance of its drug Brinsupri. The drug's revenue growth has led Insmed to increase its full-year 2026 revenue guidance for Brinsupri to $1.25 billion to $1.4 billion. These developments signify Insmed's successful transition into a broader respiratory franchise with increased combined peak sales estimates for its lead assets.
High Growth Tech Stocks in the US to Watch
The U.S. market is experiencing a significant upswing, with a 21% rise over the past year and expected 17% annual earnings growth. This article highlights high-growth tech stocks that align with these positive trends, focusing on companies with strong innovation, financial health, and market potential. It details three companies: Advanced Energy Industries (AEIS), Insmed (INSM), and Praxis Precision Medicines (PRAX), showcasing their financial performance, strategic developments, and future growth prospects.
Assenagon Asset Management S.A. Acquires 155,011 Shares of Insmed, Inc. $INSM
Assenagon Asset Management S.A. significantly increased its stake in Insmed, Inc. (NASDAQ:INSM) by 245% in the second quarter, purchasing an additional 155,011 shares to own a total of 218,270 shares valued at approximately $23.3 million. This increase follows Insmed's strong quarterly results, with revenue soaring 296.1% year over year and earnings per share beating analyst expectations. Despite continued negative net income, the company raised its 2026 revenue guidance, and analysts maintain a bullish "Buy" rating with an average price target of $205.26.
Pacer Advisors Inc. Has $1.19 Million Holdings in Insmed, Inc. $INSM
Pacer Advisors Inc. significantly reduced its stake in Insmed, Inc. by 53.3% in the first quarter, now holding 7,279 shares valued at $1.19 million. Despite this, other major institutions like Vanguard and State Street increased their holdings, and Insmed reported strong Q2 results, exceeding analyst expectations for revenue and narrowing losses. The company raised its 2026 revenue guidance, and analysts maintain a consensus "Buy" rating for INSM.
Is Insmed (INSM) Cheap After Q2 Revenue Growth And Raised Guidance?
Insmed (INSM) has seen renewed investor interest after reporting a smaller net loss and raised full-year revenue guidance in its Q2 2026 earnings. The company's stock has shown strong recent gains, despite a year-to-date decline, and is considered undervalued by Simply Wall St's narrative and DCF models, which point to significant upside potential. Key catalysts include the anticipated U.S. launch of brensocatib and upcoming Phase II data for other treatments.
Insmed (INSM) Stock Cools As BRINSUPRI Surge Recasts Growth Profile
Insmed's stock experienced a slight dip despite reporting a strong biotech quarter driven by the success of BRINSUPRI, which generated $309.2 million in Q2 revenue and has full-year guidance of $1.25 billion to $1.4 billion. The company's overall quarterly revenue reached $425.5 million, significantly narrowing its net loss. While BRINSUPRI and ARIKAYCE are showing strong performance, bear concerns focus on the long-term durability of BRINSUPRI's launch and the company's continued high spend and cash burn despite aiming for cash flow positivity by 2027.
What Insmed Stock’s Premium Is Actually Buying
Insmed (INSM) stock trades at a significant premium, 25.3 times sales, despite being 37% below its 52-week high, with this premium driven by an optimistic peak-sales estimate of over $14 billion. This estimate relies heavily on the future success of TPIP, a drug still in Phase III trials, rather than solely on its currently selling drugs like BRINSUPRI and ARIKAYCE. The company aims for cash flow positivity by 2027 without raising capital, but faces risks including TPIP's trial outcomes and the sustainability of patient starts for BRINSUPRI.
Insmed Incorporated Stock 12‑Month Price Target Raised to $197.14, Implies 99% Upside
Insmed Incorporated's average 12-month price target has been increased to $197.14, up from $195.95, with forecasts ranging from $140 to $243 per share. This new target suggests a potential upside of approximately 99% from its August 5th closing price. The consensus rating for Insmed Incorporated among 25 analysts remains a "Buy."
Insmed (NASDAQ: INSM) hits $731M 2026 product revenue as losses narrow
Insmed (NASDAQ: INSM) reported a significant increase in product revenue for Q2 2026, reaching $425.5 million, and a six-month total of $731.5 million, primarily driven by the launch of BRINSUPRI and continued growth of ARIKAYCE. The company's net loss narrowed to $13.2 million for the quarter, and it holds substantial liquidity with over $1.1 billion in cash and marketable securities. Despite ongoing operating losses due to extensive R&D and commercialization efforts, Insmed is advancing its clinical pipeline, including TPIP and gene therapies, and expects its current funds to last at least 12 months.
Insmed (INSM) Stock Looks Expensive On Sales But Strong On Returns
Insmed (INSM) stock has seen a significant surge over the past three years, yet current valuation metrics present a mixed picture. While the company's price-to-sales ratio suggests overvaluation compared to industry averages and its modeled fair value, the strong performance and anticipated success of therapies like BRINSUPRI and ARIKAYCE contribute to investor optimism. The key question for investors is whether the company's future execution can justify the high expectations currently embedded in its stock price.
Insmed (INSM) Soars 33.86% as Brinsupri Drives Fourfold Growth. Here’s What to Watch Next
Insmed (INSM) experienced a significant 33.86% surge in its share price due to a nearly fourfold increase in Q2 revenues, largely driven by its drug Brinsupri. The company's total revenues jumped 296% to $425.5 million, enabling it to slash its net loss by 96%. Following this strong performance, Insmed raised its full-year revenue guidance, with investors now watching for sustained momentum from Brinsupri and the expansion of Arikayce into new markets.
Reporting person for NASDAQ: INSM plans 27,173-share sale after prior trades
Martina Flammer, a reporting person for INSMED Inc. (NASDAQ: INSM), has filed to sell up to 27,173 shares of common stock through Merrill Lynch, with an approximate sale date of August 6, 2026. This planned sale is related to stock plan activity. The filing also discloses several previous open-market sales by Flammer between May and July 2026.
Insmed Inc Stock (INSM) Moved Up by 31.83% on Aug 6: Key Drivers Unveiled
Insmed Inc (INSM) stock surged by 31.83% due to positive clinical trial data and potential acquisition interest. Analysts have revised revenue models with an average price target of $196.74, while technical indicators suggest a sell signal and oversold conditions. The company's significant equity dilution, regulatory uncertainties, high operational cash burn, and commercial execution risks are highlighted as key challenges.
Insmed, Inc. (NASDAQ:INSM) Given Consensus Rating of "Buy" by Brokerages
Insmed, Inc. (NASDAQ:INSM) has received a consensus "Buy" rating from 26 analysts, with an average 12-month price target of $209.35. Despite recent insider selling and shares trading near their 52-week low, the company reported better-than-expected quarterly earnings with revenue up 229.7% year-over-year. Analysts anticipate Insmed will post an EPS of -2.43 for the current year.
Insmed Catapults Nearly 40%, Leading A Biotech Rally
Insmed (INSM) stock surged 30% after reporting strong second-quarter sales for its new lung disease drug, Brinsupri, exceeding analyst expectations. The company also raised its full-year guidance for the drug's sales, contributing to a broader rally in the biotech sector. This positive performance helped Insmed lead a biotech rally, contrasting with other companies like Mirum which saw declines.
FMR LLC discloses 7.4% Insmed Inc (INSM) ownership in amended 13G
FMR LLC has filed an amended Schedule 13G, disclosing a beneficial ownership of 7.4% in Insmed Inc (INSM), amounting to 16,127,583.08 shares of common stock. Abigail P. Johnson is also reported with beneficial ownership of the same number of shares, holding sole dispositive power but no voting power. FMR LLC exercises sole voting power over 15,133,671.95 shares and sole dispositive power over all 16,127,583.08 shares.
Earnings Flash (INSM) Insmed Incorporated Reports Q2 Revenue $425.5M, vs. FactSet Est of $393.7M
Insmed Incorporated (INSM) reported second-quarter revenue of $425.5 million, surpassing FactSet's estimate of $393.7 million. This financial update indicates a stronger-than-expected performance for the biotechnology company during the quarter. The article also notes other recent financial activities and analyst coverage related to Insmed.
Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
Insmed (Nasdaq: INSM) reported strong second-quarter 2026 financial results, with total company revenues of $425.5 million. The company raised its full-year 2026 BRINSUPRI revenue guidance to $1.25 billion to $1.40 billion and increased the peak revenue estimate for its three lead programs (BRINSUPRI, TPIP, ARIKAYCE) to over $14 billion combined. Key developments include significant growth for BRINSUPRI in the U.S., a sNDA submission for ARIKAYCE label expansion, and advancement of multiple clinical programs across respiratory, immunology, and neuro rare therapeutic areas.
INSMED Inc Q2 2026: Revenue $425.5M, EPS $(0.06) — 10-Q Summary
INSMED Inc reported strong financial results for Q2 2026, with revenue reaching $425.5M, a significant increase of 296% year-over-year. The company also narrowed its net loss to $(13.2M) and diluted EPS to $(0.06), driven by the successful commercial launch of BRINSUPRI and continued international growth of ARIKAYCE. INSMED is also progressing with clinical trials and expanding its operational capacity.
Insmed Number of Employees 2026 | Employee Count & Headcount Data
Insmed, Inc. (NASDAQ: INSM) had approximately 1,713 employees worldwide as of March 2026, marking a 76.1% growth from 2023. The company is actively hiring, with 192 job postings in 2026, a 32.0% increase from 2025. Insmed's workforce is concentrated in North America, and the average salary is $179,270.
InvestingPro’s fair value predicted Insmed’s 45% decline 8 months early By Investing.com
InvestingPro's Fair Value analysis accurately predicted a significant decline in Insmed (NASDAQ:INSM) shares, flagging a 38.5% overvaluation eight months before the stock plummeted 44.66%. The analysis, which combines multiple sophisticated valuation methodologies, indicated the biopharmaceutical company's intrinsic worth was significantly lower than its trading price despite impressive revenue growth. This successful prediction highlights the value of comprehensive valuation analysis in identifying mispriced opportunities and helping investors make informed decisions.
Here’s Why Baron Health Care Fund Remains Bullish on Insmed (INSM)
Baron Health Care Fund remains bullish on Insmed (INSM) despite the company's stock detracting from the fund's performance in Q2 2026. The fund believes Insmed's three lead pulmonology assets could generate over $8 billion in peak sales, with Brinsupri for non-cystic fibrosis bronchiectasis being a significant opportunity. Although sales missed expectations and caused a stock dip, Baron Capital emphasizes the long-term potential of Brinsupri and the convenience and potential efficacy of treprostinil palmitil inhalation powder (TPIP).
Earnings Preview: Insmed to Report Financial Results Pre-market on August 06
Insmed (INSM) is scheduled to release its financial results on August 06 before market open. Analysts expect the company to report an EPS of -$0.36 and revenue of $69.75 million. This will be a key event for investors to assess the company's performance and future outlook.
Insmed Slips as Traders Appear to Await Earnings Despite Recent Positive Pipeline Updates
Insmed (INSM) shares are experiencing a decline as traders seem to be anticipating upcoming earnings, despite recent positive news regarding the company's pipeline. The stock has been trading with increased volume and has seen significant short interest, with a high short float and days to cover. Investors
Insmed Stock And 2 Healthcare Names To Watch As DOJ Uncertainty Builds
This article examines three healthcare stocks that are particularly sensitive to regulatory shifts, especially concerning the Department of Justice's policies and corporate taxation. With the nomination of a new U.S. Attorney General facing delays and increased scrutiny on DOJ settlements, companies like AnaptysBio, Insmed, and Insulet are highlighted for their potential exposure and opportunities amidst this uncertainty. The article delves into each company's strengths, risks, and how evolving regulatory landscapes might impact their financial outlook and investor perception.
Insmed (INSM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Insmed (INSM) is predicted to report a year-over-year increase in earnings and higher revenues for Q2 2026. The company is expected to post a quarterly loss of $0.69 per share with revenues of $389.72 million, surpassing previous estimates. A positive Earnings ESP of +22.32% combined with a Zacks Rank #3 suggests a high probability of an earnings beat for Insmed.
Insmed Inc (INSM) Institutional Confidence
Insmed Inc (INSM) has a strong institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional ownership has increased by 0.02% quarter-over-quarter, with Stanley Druckenmiller being the largest holder despite a slight decrease in his personal holdings. Several other major institutional investors, including Darwin Global Management and JP Morgan Asset Management, also hold significant stakes in the company.
Insmed Inc (INSM) Financial Health: Profitability & Balance Sheet Analysis
Insmed Inc (INSM) has a strong financial health score of 8.56, ranking 39th in the Biotechnology & Medical Research industry, indicating stable financial status and high operating efficiency. The company reported a significant quarterly revenue increase of 229.62% year-over-year, reaching $305.96 million, with net profit growing by 36.25% year-over-year. Despite not disclosing all relevant financial data yet, its financial score improved by 0.01 from the previous score.
INSM|Insmed Inc|Price:104.080|Chg%:-0.650
Insmed Inc (INSM) is currently trading at $104.08, down 0.62%. The company's fundamentals are strong with high growth potential, and it is considered fairly valued. Analysts have a "Buy" rating on the stock, with a target price of $196.96, indicating an 84.22% upside potential despite a medium-term downward trend expectation.
Insmed Incorporated Revenue Breakdown – DUS:IM8N
Insmed Incorporated (DUS:IM8N) generated 516.32 million EUR in revenue last year, primarily from its Therapies segment. The United States was the largest contributor to its revenue, accounting for 385.65 million EUR. This represents significant growth in both its top-performing segment and its main geographical market compared to the previous year.
